# Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney Collaboratory

> **NIH NIH UM1** · JOHNS HOPKINS UNIVERSITY · 2024 · $462,279

## Abstract

Project Summary
The TARA cohort is located in Mozambique and is currently overseen by Dr. Maria Lain in collaboration with
Dr. Savita Pahwa at the University of Miami (RF1/RF4). As noted in the attached request-The TARA Cohort “is
unique in that only one third of the cohort are observed to be virologically suppressed over the first year of
ART, with the remainder showing no virologic suppression or intermittent virologic control. This cohort has
provided important insights into the capacity of the infant immune system innate and adaptive immune
responses to HIV through natural exposure to autologous virus. The cohort has also contributed to the
development of novel single-cell technologies to probe the immune responses to HIV at the single-cell level,
with critical importance to assay development planned in RF4 for more widespread application. The second
cohort is the Ucwaningo Lwabantwana Cohort in KwaZulu- Natal, South Africa, overseen by Dr. Moherndran
Archary in collaboration with Dr. Philip Goulder (RF2). The cohort has been enrolling mother-child pairs since
2015 and has enrolled over 266 pairs. The funding requested is necessary for each of the teams to continue to
maintain the cohort to complete the scheduled visits, as well as processing and storage of blood samples for
the study questions. Pivotal to Pediatric HIV Cure research, is the novel scientific finding of sex differences in
susceptibility to in utero HIV infection and remission outcomes. In this cohort, Dr. Goulder and his colleagues
have reported on increase susceptibility of females to in utero HIV and remission outcomes in males only.
Maintenance of this cohort is quintessential to understanding sex differences in perinatal HIV infection. The
third cohort for which support is being requested is for the Gold Study cohort. This Cohort is based at the
Family Centre for Research with Ubuntu (FAMCRU) at Stellenbosch University, where Dr. Mark Cotton is the
PI (RF1), as well as at the Perinatal HIV Research Unit (PHRU) at Wits Health Consortium, where Dr. Caroline
Tiemessen is the PI (RF1). This cohort is critical for the successful completion of the ongoing CNS studies
underway through a supplement to the PAVE MDC from the Office of AIDS Research. This cohort is
approximately 40 participants at each site. The support requested will cover the costs of the yearly health
checks, as well as monthly peer support groups, for research participation and discussions around spinal taps
and neuroimaging to assess CNS as a reservoir in perinatal infection. These activities are deemed as critical
for study retention, which will ultimately impact on the scientific discoveries within PAVE.

## Key facts

- **NIH application ID:** 11086478
- **Project number:** 3UM1AI164566-04S3
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** Ann M Chahroudi
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $462,279
- **Award type:** 3
- **Project period:** 2024-05-15 → 2026-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11086478

## Citation

> US National Institutes of Health, RePORTER application 11086478, Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney Collaboratory (3UM1AI164566-04S3). Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/grant/nih/11086478. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*